Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Deferred Taxes: 2013-2021

Historic Deferred Taxes for Amphastar Pharmaceuticals (AMPH) over the last 2 years, with Dec 2021 value amounting to $2.8 million.

  • Amphastar Pharmaceuticals' Deferred Taxes fell 26.79% to $2.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was $2.9 million, marking a year-over-year decrease of 46.39%. This contributed to the annual value of $17.9 million for FY2024, which is 42.09% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Deferred Taxes of $2.8 million as of Q4 2021, which was down 26.79% from $3.8 million recorded in Q4 2020.
  • Amphastar Pharmaceuticals' 5-year Deferred Taxes high stood at $5.3 million for Q4 2019, and its period low was -$2.0 million during Q3 2020.
  • For the 3-year period, Amphastar Pharmaceuticals' Deferred Taxes averaged around $1.7 million, with its median value being $2.8 million (2021).
  • Data for Amphastar Pharmaceuticals' Deferred Taxes shows a maximum YoY fell of 28.71% (in 2020) over the last 5 years.
  • Over the past 3 years, Amphastar Pharmaceuticals' Deferred Taxes (Quarterly) stood at $5.3 million in 2019, then decreased by 28.71% to $3.8 million in 2020, then fell by 26.79% to $2.8 million in 2021.
  • Its last three reported values are $2.8 million in Q4 2021, $3.8 million for Q4 2020, and -$2.0 million during Q3 2020.